Secukinumab retention in PsA: Study of 170 pts, 13% B27+, most w/ peripheral arthritis &70% on 150 mg/mo. Median ret
Tweet Content
Secukinumab retention in PsA: Study of 170 pts, 13% B27+, most w/ peripheral arthritis &70% on 150 mg/mo. Median retention 636 days. Peripheral arthritis was a predictor of better retention (HR 0.424). https://t.co/aZD9qD0jxm https://t.co/FlqRlcAZd1
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off